Lupin 2023

Camber adds Linezolid for Oral Suspension to portfolio

Print Friendly, PDF & Email

PISCATAWAY, N.J. – Camber Pharmaceuticals announces the addition of Linezolid for Oral Suspension to its current portfolio.

Linezolid for Oral Suspension is indicated for the treatment of nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and resistant isolates) or Streptococcus pneumoniae.

Linezolid for Oral Suspension is available in a 100 mg/5 mL strength and supplied in a 150 mL bottle.

To find out more about Linezolid for Oral Suspension please

Comments are closed.